MedImmune Presents Data from Its Advancing Inflammatory Disease Portfolio at 71st Annual Meeting of the American College of Rheumatology
2007 NOV 19 -- MedImmune, Inc. announced it will present 11 abstracts at the 71st Annual Meeting of the American College of Rheumatology, demonstrating the company's breadth of ongoing, multi-stage research evaluating the origins and effects of inflammatory disease and novel disease pathways. "MedImmune is pleased to present data that may provide significant insights into the nature of systemic autoimmune diseases as well as potential new treatment options for patients in need," said Barbara White, M.D., vice president, clinical development, inflammatory disease. Investigators will present results from eight studies in systemic lupus erythematosus (SLE), one in scleroderma, one in rheumatoid arthritis and one evaluating therapeutic B-cell depletion across multiple autoimmune diseases. "The research presented at ACR exemplifies MedImmune's pioneering role in identifying new pathways involved in rheumatic disease and developing targeted monoclonal antibodies (MAbs) as potential treatments," said Anthony Coyle, Ph.D., vice president, respiratory, inflammation and autoimmune disease research. Keywords: Monoclonal Antibodies, Arthritis, Autoimmune Disease, Autoimmune Disorder, Biotechnology, Biotechnology Business, Biotechnology Company, Immunology, MedImmune Inc., Monoclonal Antibody, Rheumatic Disease, Rheumatoid Arthritis, Rheumatology, Systemic Lupus Erythematosus, MedImmune Inc. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
|
